Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2022 | Correction

Correction to: Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis

Authors: Liling Wen, Huanzi Lu, Qiusheng Li, Qunxing Li, Shuqiong Wen, Dikan Wang, Xi Wang, Juan Fang, Jun Cui, Bin Cheng, Zhi Wang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2022

Excerpt

Correction to: J Exp Clin Cancer Res 38, 299 (2019) …

Wen L, Lu H, Li Q, et al. Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis. J Exp Clin Cancer Res. 2019;38:299. https://doi.org/10.1186/s13046-019-1185-0.CrossRefPubMedPubMedCentral

Title: Correction to: Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis
Authors: Liling Wen
Huanzi Lu
Qiusheng Li
Qunxing Li
Shuqiong Wen
Dikan Wang
Xi Wang
Juan Fang
Jun Cui
Bin Cheng
Zhi Wang
Publication date: 01-12-2022
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2022
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-022-02364-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment

LINC00629 protects osteosarcoma cell from ER stress-induced apoptosis and facilitates tumour progression by elevating KLF4 stability

ALKBH5-mediated m6A modification of circCCDC134 facilitates cervical cancer metastasis by enhancing HIF1A transcription

A novel protein encoded by ZCRB1-induced circHEATR5B suppresses aerobic glycolysis of GBM through phosphorylation of JMJD5

A roadmap for translational cancer glycoimmunology at single cell resolution

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax

Keynote webinar | Spotlight on antibody–drug conjugates in cancer